EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens

Swati Satturwar iD, Nada Shaker, William Sinclair, Rulong Shen, Anil V Parwani, Qingqing Ding, Zaibo Li iD

Cancer Cytopathology · 2023

DOI: 10.1002/cncy.22708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cytopathology, 2023. Verfasst von Swati Satturwar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Adenocarcinoma, Carcinoma, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SOX17 (SRY‐box transcription factor 17) was recently identified as a highly sensitive and specific marker for ovarian and endometrial carcinomas in surgical specimens. In this study, validation of the utility of SOX17 immunohistochemistry (IHC) in diagnosing metastatic gynecologic carcinomas in cytology specimens was sought.

Methods

The study cohort included 84 cases of metastatic carcinomas that included 29 metastatic gynecologic carcinomas (24 ovarian high‐grade serous carcinomas, two endometrial serous carcinomas, one low‐grade serous carcinoma, one ovarian clear cell carcinoma, and one endometrial endometrioid carcinoma) and 55 cases of metastatic nongynecologic carcinomas (10 clear cell renal cell carcinomas, 10 papillary thyroid carcinomas, 11 gastrointestinal adenocarcinomas, 10 breast carcinomas, 10 lung adenocarcinomas, and four urothelial carcinomas). Cytology specimen types included peritoneal fluid ( n = 44), pleural fluid ( n = 25), and fine‐needle aspiration ( n = 15). SOX17 IHC was performed on the cell block sections. The intensity of staining and percent positivity of the tumor cells were evaluated.

Results

SOX17 was highly expressed in all tested metastatic gynecologic carcinomas with diffuse and strong nuclear expression (29 of 29; 100%). SOX17 was negative in other metastatic nongynecologic carcinomas (54 of 55; 98.18%) except for one papillary thyroid carcinoma that showed low positivity (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsAdenocarcinomaCarcinomaCystadenocarcinoma, SerousHumansFemaleBiomarkers, TumorSOXF Transcription Factors

Stichwörter der Autor:innen

PAX8SOX17cytologyimmunohistochemistrymarkermetastatic gynecologic malignancies

Substanzen

Biomarkers, TumorSOX17 protein, humanSOXF Transcription Factors

Autor:innen und Institutionen

  • Department of Pathology, The Ohio State University, Columbus, Ohio, USA.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Swati Satturwar, Zaibo Li

Zitieren

APA

Satturwar, S., Shaker, N., Sinclair, W., Shen, R., Parwani, A. V., Ding, Q., & Li, Z. (2023). SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens. Cancer Cytopathology. https://doi.org/10.1002/cncy.22708

Vancouver

Satturwar S, Shaker N, Sinclair W, Shen R, Parwani AV, Ding Q, et al. SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens. Cancer Cytopathology. 2023. doi:10.1002/cncy.22708

BibTeX
@article{Satturwar2023,
  author = {Satturwar, Swati and Shaker, Nada and Sinclair, William and Shen, Rulong and Parwani, Anil V and Ding, Qingqing and Li, Zaibo},
  title = {SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens},
  journal = {Cancer Cytopathology},
  year = {2023},
  doi = {10.1002/cncy.22708}
}
Kostenlos starten →